Showing 3004 results
-
Story /The roots of Novartis reach back more than 250 years, to the chemical and scientific traditions that helped shape modern healthcare. Thirty years after its creation, a legacy of discovery and curiosity continues to guide its pursuit of new possibilities for patients.
-
Press release /Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goalsNew AZALEA-TIMI 71 analyses will further characterize the bleeding…
-
Press release /NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary…
-
Press release /Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III…
-
Press release /Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings…